Flag of the European Union EU Clinical Trials Register Help

Clinical trials for b

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7380   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12,925 result(s) found for: b. Displaying page 644 of 647.
    «« First « Previous 639  640  641  642  643  644  645  646  647  Next»
    EudraCT Number: 2006-003560-62 Sponsor Protocol Number: R092670PSY3006 Start Date*: 2007-03-28
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects with Schi...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) LT (Completed) DE (Completed) AT (Completed) FR (Completed) CZ (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-002111-82 Sponsor Protocol Number: 42603ATT3013 Start Date*: 2007-10-24
    Sponsor Name:Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...
    Medical condition: Attention Deficit-Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) NL (Completed) DK (Completed) FI (Completed) BE (Completed) GB (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004140-23 Sponsor Protocol Number: 27298 Start Date*: 2007-06-06
    Sponsor Name:Merck Serono Int, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt, Germany
    Full Title: A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa anta...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) BE (Completed) BG (Completed) PT (Completed) ES (Completed) GR (Completed) IT (Completed) NL (Completed) SE (Completed) FI (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-018001-51 Sponsor Protocol Number: ING111762 Start Date*: 2010-11-10
    Sponsor Name:Viiv Healthcare S. L
    Full Title: Estudio de Fase III aleatorizado, doble ciego, para evaluar la seguridad y eficacia de 50 mg una vez al día de GSK1349572 frente a 400 mg dos veces al día de Raltegravir, ambos administrados en com...
    Medical condition: Sujetos adultos infectados por el VIH-1, que han recibido tratamiento antirretroviral previo con la excepción de un inhibidor de la integrasa.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008922 Chronic infection with HIV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) GR (Completed) IT (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-002780-27 Sponsor Protocol Number: GAL-ALZ-3005 Start Date*: 2008-08-26
    Sponsor Name:Janssen Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-severe Alzheimer’s Disease
    Medical condition: Mild to moderately severe Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) LT (Completed) LV (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) AT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-018070-64 Sponsor Protocol Number: 28431754DIA3012 Start Date*: 2010-05-12
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26 Week Multicenter Study with a 26-Week Extension to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 (Canagli...
    Medical condition: Type 2 Diabetes Mellitus With Inadequate Glycemic Control
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) DE (Completed) PT (Prematurely Ended) FR (Completed) ES (Completed) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014290-40 Sponsor Protocol Number: DU176b-D-U305 Start Date*: 2010-02-10
    Sponsor Name:Daiichi Sankyo Development Limited
    Full Title: A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/warfar...
    Medical condition: Reduction of the risk of symptomatic recurrent venous thromboembolic complications in patients with acute symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    14.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) SE (Completed) FR (Completed) EE (Completed) BE (Completed) AT (Completed) ES (Completed) DK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002522-29 Sponsor Protocol Number: 352.2046 Start Date*: 2008-10-08
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulm...
    Medical condition: Chronic obstructive pulmonary disease (COPD). Enfermedad Pulmonar Obstructiva Crónica.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) BE (Completed) DE (Completed) GB (Completed) DK (Completed) NL (Completed) HU (Completed) IT (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-003784-32 Sponsor Protocol Number: 20050201 Start Date*: 2007-05-02
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer
    Medical condition: Subjects with unresectable stage IIIB with pericardial or pleural effusion or stage IV or recurrent Non Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) AT (Completed) FR (Completed) CZ (Completed) DE (Completed) HU (Completed) IT (Completed) GR (Completed) SK (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006170-28 Sponsor Protocol Number: E2007-G000-307 Start Date*: 2008-09-15
    Sponsor Name:Eisai Ltd
    Full Title: An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-scalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy i...
    Medical condition: Epilepsy: refractory partial seizures with or without secondary generalisation
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) AT (Completed) BE (Completed) PT (Completed) LT (Completed) NL (Completed) HU (Completed) FR (Completed) GB (Completed) SE (Completed) EE (Completed) LV (Completed) DK (Completed) IT (Completed) DE (Completed) FI (Completed) BG (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-001523-57 Sponsor Protocol Number: IM101179 Start Date*: 2011-06-10
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: Multicenter, Open-Label Study to Assess Early Response to Abatacept with Background Methotrexate Using Power Doppler Ultrasonography in Patients with Active Rheumatoid Arthritis and Inadequate Resp...
    Medical condition: Adult subjects with active rheumatoid arthritis (RA) according to the American Rheumatism Association criteria for the classification of RA and with inadequate response to methotrexate
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) DK (Completed) FR (Completed) ES (Completed) GB (Completed) IT (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015476-98 Sponsor Protocol Number: 1200.75 Start Date*: 2010-05-17
    Sponsor Name:Boehringer Ingelheim
    Full Title: LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one pri...
    Medical condition: patients with metastatic HER2 over-expressing breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) BE (Completed) DE (Completed) SK (Completed) PT (Completed) CZ (Completed) FR (Completed) AT (Completed) IT (Completed) ES (Completed) FI (Prematurely Ended) LT (Completed) LV (Completed) SI (Completed) GB (Completed) IE (Prematurely Ended) NO (Completed)
    Trial results: View results
    EudraCT Number: 2006-001623-18 Sponsor Protocol Number: EGF102988 Start Date*: 2006-12-07
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or P...
    Medical condition: Resected Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041823 Squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IE (Completed) GR (Completed) AT (Completed) SK (Completed) GB (Completed) DE (Completed) CZ (Completed) PT (Prematurely Ended) EE (Completed) HU (Completed) IT (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023437-30 Sponsor Protocol Number: A7281006 Start Date*: 2011-09-29
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN SUBJECTS WITH CROHN’S DISEASE(OPERA)
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) SE (Completed) AT (Completed) DE (Completed) PT (Prematurely Ended) NO (Completed) NL (Completed) ES (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-000023-15 Sponsor Protocol Number: H7T-MC-TAAL Start Date*: 2005-02-10
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention
    Medical condition: Reduction of atherothrombotic events in patients with acute coronary syndromes (ACS) that is patients with ST-segment elevation MI [STEMI], non-ST-segment elevation MI [NSTEMI], or unstable angina...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10011085 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) FI (Completed) HU (Completed) CZ (Completed) SK (Completed) DE (Completed) IT (Completed) LT (Completed) EE (Completed) LV (Completed) IS (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002323-25 Sponsor Protocol Number: AA1720 Start Date*: 2017-09-22
    Sponsor Name:Center for cancer immune therapy
    Full Title: Adoptive cell therapy across cancer diagnoses
    Medical condition: Patients with metastatic solid cancers in stages III or IV regardless of diagnosis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055099 Ocular cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055100 Otic cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055108 Thymic cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050017 Lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055104 Pharyngeal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055105 Sinus cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055096 Anal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053548 Gastrointestinal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055097 Rectal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055114 Colon cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055098 Oral cavity cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055109 Tongue cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055102 Oesophageal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050018 Renal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046394 Ureteric cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046433 Urethral cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055115 Skin cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055101 Bone cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055095 Adrenal gland cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055106 Pituitary cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055107 Thyroid cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055111 Biliary cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066879 Gallbladder cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055110 Hepatic cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055094 Cervix cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016182 Fallopian tube cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033158 Ovarian epithelial cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046887 Vaginal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047742 Vulval cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055103 Testicular cancer metastatic PT
    20.0 100000016906 10033605 Pancreatic cancer metastatic LLT
    20.0 100000016840 10023183 Jejunum cancer metastatic LLT
    20.0 100000016840 10013816 Duodenal cancer metastatic LLT
    20.0 100000016840 10023167 Jejunal cancer metastatic LLT
    20.0 100000017543 10038498 Renal pelvis and ureter transitional cell cancer metastatic LLT
    20.0 100000017543 10038509 Renal pelvis and ureteric cancer metastatic transitional cell LLT
    20.0 100000017725 10046377 Ureter cancer metastatic LLT
    20.0 100000017773 10046420 Urethra cancer metastatic LLT
    20.0 100000021146 10036947 Prostatic cancer metastatic LLT
    20.0 100000016931 10062478 Esophageal cancer metastatic LLT
    20.0 100000143841 10063107 Tubular breast cancer metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068694 Testicular germ cell cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068971 Germ cell cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069728 Rectosigmoid cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069730 Large cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070902 Laryngeal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072792 Tonsil cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079104 Nasopharyngeal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-016839-35 Sponsor Protocol Number: PX-171-009 Start Date*: 2010-09-07
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: Estudio en fase 3 multicéntrico y aleatorizado de comparación de carfilzomib, lenalidomida y dexametasona (CRd) con lenalidomida y dexametasona (Rd) en pacientes con mieloma múltiple recidivado. A...
    Medical condition: Mieloma múltiple. Multiple myeloma.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) BE (Completed) NL (Completed) CZ (Completed) DE (Completed) AT (Completed) BG (Completed) FR (Completed) HU (Completed) SE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005101-36 Sponsor Protocol Number: LPS14584 Start Date*: 2016-05-06
    Sponsor Name:sanofi-aventis Groupe
    Full Title: A 24-Week, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo® and Tresiba® in Insulin-Naive Patients with Type 2 Diabetes Mellitus Not Adequately...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) GR (Completed) HU (Completed) CZ (Completed) SK (Completed) FR (Completed) GB (Completed) SI (Completed) BG (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004022-87 Sponsor Protocol Number: A6181111 Start Date*: 2007-04-05
    Sponsor Name:Pfizer Inc. [...]
    1. Pfizer Inc.
    2. Pfizer bv CR
    3. Pfizer bv RA
    Full Title: A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS
    Medical condition: Progressive, advanced/metastatic well-differentiated pancreatic islet cell tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033632 Pancreatic neoplasms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed) DK (Prematurely Ended) BE (Completed) FR (Completed) DE (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021258-20 Sponsor Protocol Number: EAST Start Date*: 2011-06-15
    Sponsor Name:Kompetenznetz Vorhofflimmern e.V. (AFNET)
    Full Title: Early treatment of Atrial fibrillation for Stroke prevention Trial (EAST)
    Medical condition: Atrial fibrillation, stroke, heart failure, myocardial infarction, cognitive dysfunction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    20.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    21.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    20.0 10037175 - Psychiatric disorders 10009841 Cognitive and attention disorders and disturbances HLGT
    20.0 10007541 - Cardiac disorders 10028596 Myocardial infarction PT
    21.1 10029205 - Nervous system disorders 10019016 Haemorrhagic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) NL (Completed) CZ (Completed) BE (Completed) ES (Completed) PL (Completed) IT (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 639  640  641  642  643  644  645  646  647  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Aug 12 21:04:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA